Does Preoperative Use of Dutasteride Decrease Bleeding During Open Prostatectomy?

Basit Öğe Kaydı
dc.authoridOzcan, Serkan/0000-0002-2459-139X
dc.authoridKilinc, Muhammet Fatih/0000-0002-2515-7106
dc.contributor.authorDemirbas, Arif
dc.contributor.authorResorlu, Berkan
dc.contributor.authorGulpinar, Murat Tolga
dc.contributor.authorKardas, Sina
dc.contributor.authorDoluoglu, Omer Gokhan
dc.contributor.authorTepeler, Abdulkadir
dc.contributor.authorKilinc, Muhammet Fatih
dc.date.accessioned2025-01-27T20:16:31Z
dc.date.available2025-01-27T20:16:31Z
dc.date.issued2018
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractPurpose: To investigate whether use of dutasteride, a 5-alpha reductase inhibitor, for at least four weeks preoperatively affected the blood loss during open prostatectomy (OP). Materials and methods: Retrospective analysis was made of the data of 110 patients who had undergone OP. Group I comprised 50 patients that used dutasteride for 4 weeks preoperatively, and Group II comprised 60 patients that did not use the drug. The groups were compared in respect of age, total prostate specific antigen (TPSA) levels, prostate volumes, preoperative hemoglobin (Hgb) and hematocrit (Hct) levels, postoperative reduction of Hgb and Hct, percentage reduction in Hgb and Hct, and the administration of postoperative blood products. Results: No differences were determined between the two groups in respect of prostate volumes, TPSA, preoperative Hgb and Hct levels (P = .813, P = .978, P = .422, P = .183, respectively). Postoperative Hgb reduction was 2.19 +/- 1.36 g/dL in Group I, and 2.5 +/- 1.47 g/dL in Group 11 (P = .260). Hgb reduction was calculated as 16.4 +/- 9.7% in Group I and 17.6 +/- 9.7% in Group II (P = .505). Reductions in Hct were 5.8 +/- 3.7% in Group I, and 7.3 +/- 4.4% in Group II, and percent reductions were 14.8 +/- 9.4% in Group I and 17.3 +/- 10.2% in Group II (P = .068, P = .182, respectively). Conclusion: The use of dutasteride before OP did not affect blood loss during surgery, therefore surgery should not be delayed for the administration of dutasteride to patients.
dc.identifier.endpage52
dc.identifier.issn1735-1308
dc.identifier.issn1735-546X
dc.identifier.issue1
dc.identifier.pmid29150830
dc.identifier.scopus2-s2.0-85051607539
dc.identifier.scopusqualityQ3
dc.identifier.startpage48
dc.identifier.urihttps://hdl.handle.net/20.500.12428/21264
dc.identifier.volume15
dc.identifier.wosWOS:000431094400009
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherUrol & Nephrol Res Ctr-Unrc
dc.relation.ispartofUrology Journal
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20250125
dc.subjectprostate
dc.subjectopen prostatectomy
dc.subjectdutasteride
dc.subjectbleeding
dc.titleDoes Preoperative Use of Dutasteride Decrease Bleeding During Open Prostatectomy?
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu